Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Eur J Med Res. 2020 Aug 3;25(1):30. doi: 10.1186/s40001-020-00432-3.
More severe cases of COVID- 19 are more likely to be hospitalized and around one-fifth, needing ICU admission. Understanding the common laboratory features of COVID-19 in more severe cases versus non-severe patients could be quite useful for clinicians and might help to predict the model of disease progression. This systematic review and meta-analysis aimed to compare the laboratory test findings in severe vs. non-severe confirmed infected cases of COVID-19.
Electronic databases were systematically searched in PubMed, EMBASE, Scopus, Web of Science, and Google Scholar from the beginning of 2019 to 3rd of March 2020. Heterogeneity across included studies was determined using Cochrane's Q test and the I statistic. We used the fixed or random-effect models to pool the weighted mean differences (WMDs) or standardized mean differences and 95% confidence intervals (CIs).
Out of a total of 3009 citations, 17 articles (22 studies, 21 from China and one study from Singapore) with 3396 ranging from 12 to1099 patients were included. Our meta-analyses showed a significant decrease in lymphocyte, monocyte, and eosinophil, hemoglobin, platelet, albumin, serum sodium, lymphocyte to C-reactive protein ratio (LCR), leukocyte to C-reactive protein ratio (LeCR), leukocyte to IL-6 ratio (LeIR), and an increase in the neutrophil, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, blood urea nitrogen (BUN), creatinine (Cr), erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP), Procalcitonin (PCT), lactate dehydrogenase (LDH), fibrinogen, prothrombin time (PT), D-dimer, glucose level, and neutrophil to lymphocyte ratio (NLR) in the severe group compared with the non-severe group. No significant changes in white blood cells (WBC), Creatine Kinase (CK), troponin I, myoglobin, IL-6 and K between the two groups were observed.
This meta-analysis provides evidence for the differentiation of severe cases of COVID-19 based on laboratory test results at the time of ICU admission. Future well-methodologically designed studies from other populations are strongly recommended.
COVID-19 更严重的病例更有可能住院,大约五分之一的患者需要入住 ICU。了解 COVID-19 重症患者与非重症患者的常见实验室特征对于临床医生来说非常有用,并且可能有助于预测疾病进展模式。本系统评价和荟萃分析旨在比较 COVID-19 确诊感染的重症与非重症患者的实验室检查结果。
从 2019 年年初到 2020 年 3 月 3 日,我们在 PubMed、EMBASE、Scopus、Web of Science 和 Google Scholar 等电子数据库中进行了系统检索。使用 Cochrane's Q 检验和 I 统计量来确定纳入研究之间的异质性。我们使用固定或随机效应模型来汇总加权均数差(WMD)或标准化均数差和 95%置信区间(CI)。
在总共 3009 条引用中,有 17 篇文章(22 项研究,其中 21 项来自中国,1 项来自新加坡)纳入了 3396 名患者,范围从 12 至 1099 例。我们的荟萃分析显示,重症组的淋巴细胞、单核细胞和嗜酸性粒细胞、血红蛋白、血小板、白蛋白、血清钠、淋巴细胞与 C 反应蛋白比值(LCR)、白细胞与 C 反应蛋白比值(LeCR)、白细胞与白细胞介素-6 比值(LeIR)显著降低,中性粒细胞、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素、血尿素氮(BUN)、肌酐(Cr)、红细胞沉降率(ESR)、C 反应蛋白(CRP)、降钙素原(PCT)、乳酸脱氢酶(LDH)、纤维蛋白原、凝血酶原时间(PT)、D-二聚体、血糖水平和中性粒细胞与淋巴细胞比值(NLR)显著升高。两组间白细胞(WBC)、肌酸激酶(CK)、肌钙蛋白 I、肌红蛋白、白细胞介素-6 和 K 无显著变化。
本荟萃分析为基于 ICU 入院时实验室检查结果对 COVID-19 重症病例进行鉴别提供了证据。强烈建议未来来自其他人群的设计方法学良好的研究。